What type of antibiotic does Fidaxomicin belong to and its antibacterial mechanism detailed explanation

Fidaxomicin is a new type of macrolide antibiotic, but it is significantly different from traditional macrolides (such as erythromycin, azithromycin, etc.). It has a unique chemical structure and belongs to the 18-membered macrolides, while traditional macrolides mostly have 14- or 15-membered rings. This difference gives fidaxomicin unique pharmacological properties and selectivity. Clinically, fidaxomicin is mainly used to treat Clostridium difficile-associated diarrhea (CDAD), especially for patients with a high risk of recurrence or who require long-term treatment for control. Compared with other antibiotics, it has outstanding selective bactericidal effect on Clostridium difficile and has relatively little interference with normal intestinal flora.

In terms of antibacterial mechanism, the main target of fidaxomicin is bacterial RNA polymerase. It can bind and inhibit RNA polymerase at the initiation stage of transcription, preventing the synthesis of Clostridium difficile mRNA, thereby inhibiting protein production and ultimately leading to bacterial death. This is different from the mechanism by which traditional macrolides inhibit bacterial ribosomal protein synthesis. Therefore, fidaxomicin not only avoids cross-resistance with other commonly used macrolide antibiotics, but also has a lower incidence of resistance. Due to its unique mechanism of action, its bactericidal effect on Clostridium difficile is more durable and helps reduce the recurrence rate.

In terms of pharmacokinetics, fidaxomicin is almost not absorbed after oral administration and mainly acts locally on the gastrointestinal tract, so systemic adverse reactions are minimal. This feature allows it to focus on the lesion site when treating Clostridium difficile infection while avoiding effects on other organs throughout the body. Its metabolite OP-1118 also has certain antibacterial activity, further enhancing the clinical efficacy. Compared with traditional therapeutic drugs such as vancomycin and metronidazole, fidaxomicin is not only equally effective, but even better at reducing the recurrence rate. It is especially suitable for people with multiple recurrences or high-risk groups.
In summary, Fidaxomicin, as a new macrolide antibiotic, shows unique advantages in fighting Clostridium difficile infection. It works by inhibiting the initiation of RNA polymerase transcription. It has the characteristics of strong selectivity, low drug resistance rate, and low risk of recurrence. At the same time, it reduces systemic side effects because it mainly acts locally. In clinical practice, fidaxomicin is considered an important option for the treatment of Clostridium difficile-associated diarrhea, especially in patients with recurrent or severe disease.
Reference link: https://www.drugs.com